Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sharp Therapeutics's Other Operating Expense for the
three
months ended in Dec. 2025 was C$0.03 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was C$0.14 Mil.
Sharp Therapeutics's quarterly Other Operating Expense
increased
from Jun. 2025 (C$0.03 Mil) to Sep. 2025 (C$0.04 Mil) but then
declined
from Sep. 2025 (C$0.04 Mil) to Dec. 2025 (C$0.03 Mil).
Sharp Therapeutics's annual Other Operating Expense
increased
from Dec. 2023 (C$0.15 Mil) to Dec. 2024 (C$3.01 Mil) but then
declined
from Dec. 2024 (C$3.01 Mil) to Dec. 2025 (C$0.14 Mil).
Sharp Therapeutics Other Operating Expense Related Terms
Sharp Therapeutics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of C$0.14 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Other Operating Expense of C$0.14 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Other Operating Expense too high?
Sharp Therapeutics' current Other Operating Expense is C$0.14 Mil. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Other Operating Expense compare to VRTX and REGN?
Sharp Therapeutics' Other Operating Expense of C$0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Other Operating Expense is C$0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Other Operating Expense of C$0.14 Mil. The current Other Operating Expense is C$0.14 Mil. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Other Operating Expense is C$0.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score
Get the complete analysis for TSXV:SHRX
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
